Genomic Health — Q3 2019 Earnings Presentation
16 slides from Genomic Health's earnings presentation, Oct 30, 2019
Slide 1: Safe harbor statement: Cautionary Statement
Safe harbor statement 2 Cautionary Statement This presentation contains statements, including statements regarding the proposed acquisition of Genomic Health, Inc. (“Genomic Health”) by Exact Sciences Corporation (“Exact Sciences”) that are forward-looking statements within the meaning of Section 27
Slide 2: Safe harbor statement: Additional Information
Safe harbor statement 3 Additional Information In connection with the proposed transaction, Exact Sciences has filed with the SEC a registration statement on Form S-4 (File No. 333-233538), which includes a prospectus of Exact Sciences and a proxy statement of Genomic Health (the “proxy statement/pr
Slide 3: What we'll cover today
Exact Sciences is positioned for long-term, sustainable growth What we’ll cover today 4 Q3 financial results and guidance Progress on 2019 priorities
Slide 4: Third-quarter 2019 financials
5 Third-quarter 2019 financials Revenue $218.8 million $118.3 million Completed tests 456,000 241,000 Gross margin 76% 75% Operating expense $201.7 million $129.2 million Cash utilization $78.9 million $36.9 million Ending cash balance $1.2 billion $1.2 billion Q3 2019 Q3 2018
Slide 5: 2019 Corporate Priorities
Power the Partnership Enhance Cologuard Advance Liquid Biopsy 2019 Corporate Priorities 6
Slide 6: Power the partnership
7 Power the partnership Primary care, GI, and OBGYN sales teams Marketing campaign Powerful partnership Payer relationships Capturing 40% of CRC screening market from 5% today
Slide 7: Power the partnership: Robust infrastructure to support growth
8 Power the partnership Robust infrastructure to support growth
Slide 8: +19M average risk people
9 +19M average risk people Sources: US Census data and CDC NHIS survey results as published in the CDC’s MMWR between 2006 and 2017; Exact Sciences estimate assuming ~106 million total average-risk, asymptomatic people ages 45-85, ~19M ages 45-49, average revenue per test of $500-$525, and 3-year in
Slide 9: Enhance Cologuard: Cologuard 2.0 performance with new markers
10 Enhance Cologuard Cologuard 2.0 performance with new markers and lab processes in a study of 725 samples N=51 N=37 N=23 N=6 Sensitivity for CRC Current vs. new markers Current markers 87% specificity New markers 92% specificity Difference CRC sensitivity 88% 92% +4% AA sensitivity 53% 65% +12% Re
Slide 10: BLUE-C Enhance Cologuard
11 BLUE-C Enhance Cologuard Goals of prospective CRC screening study, intended for FDA submission 10,000 patients Stool and blood collection Performance validation for Cologuard 2.0 & blood test Note: Cologuard 2.0 is not approved by the FDA; for more information visit clinicaltrials.gov
Slide 11: Initiating the Voyage study
12 Enhance Cologuard Initiating the Voyage study to further evaluate real-world impact on screening, incidence, and mortality rates 150K patients 7 years For more information visit https://clinicaltrials.gov/ct2/show/NCT04124406?id=NCT04124406&rank=1
Slide 12: Planned Genomic Health combination provides strong platform for growth
13 Best-in-class R&D and clinical organization Unparalleled commercial scale with global infrastructure Enhanced financial strength Advance liquid biopsy Planned Genomic Health combination provides strong platform for continued growth
Slide 13: Advance liquid biopsy
14 Advance liquid biopsy New data at AASLD* Additional data in 2020 Test available in 2H20 5+ years of research High accuracy, low-cost platform Collecting blood and stool in BLUE-C Tests for liver and colorectal cancer Liver Colon blood *Presenting abstract at the AASLD Liver Meeting on November 10
Slide 14: 2019 Corporate Priorities
Power the Partnership Enhance Cologuard Advance Liquid Biopsy 2019 Corporate Priorities 15
Slide 15: 2019 Corporate Priorities
2019 Corporate Priorities Power the Partnership x Enhance Cologuard Advance Liquid Biopsy
Slide 16: Exact Sciences
EXACT SCIENCES